Treating newly diagnosed epilepsy: The Canadian choice

Canadian Journal of Neurological Sciences

Volumn 34, Issue 2, 2007, Pages 230-236

  Burneo, Jorge G ^a,b   McLachlan, R S ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ABSENCE; ARTICLE; CANADA; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEALTH SURVEY; HUMAN; MEDICAL SPECIALIST; MYOCLONUS EPILEPSY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVATE PRACTICE; SEX DIFFERENCE; TREATMENT FAILURE; VAGUS NERVE STIMULATION;

EID: 34347257726     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100006107     Document Type: Article

References (21)

1. Wheless JW, Venkataraman V. New formulations of drugs in epilepsy. Expert Opin Pharmacother. 1999;1(1):49-60.
2. Nadkarni S, LaJoie J, Devinsky O. Current treatments of epilepsy. Neurology. 2005;64(12 Suppl 3):S2-11.
3. Guyatt GH, Rennie D. Users' Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press; 2002.
4. Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick D. Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract. 2000;6(2):205-14.
5. Privitera MD. Evidence-based medicine and antiepileptic drugs. Epilepsia. 1999;40 Suppl 5:S47-56.
6. Montori VM, Swiontkowski MF, Cook DJ. Methodologic issues in systematic reviews and meta-analyses. Clin Orthop Relat Res. 2003(413):43-54.
7. Burneo JG, Montori VM, Faught E. Magnitude of the placebo effect in randomized trials of antiepileptic agents. Epilepsy Behav. 2002;3(6):532-4.
8. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-9.
9. French JA, Kanner AM, Bautista J, Abou-Khaul B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62(8):1261-73.
10. French JA, Kanner AM, Bautista J, Abou-Khaul B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62(8):1252-60.
11. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology. 2002;58(8 Suppl 5):S2-8.
12. Brodie MJ. Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia. 1999;40 Suppl 6:S17-22; discussion S73-4.
13. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334(3):168-75.
14. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 2005;7 Suppl 1:S1-64; quiz S5-7.
15. Semah F, Picot MC, Derambure P, Dupont S, Vercueil L, Chassagnon S, et al. The choice of antiepileptic drugs in newly diagnosed epilepsy: a national French survey. Epileptic Disord. 2004;6(4):255-65.
16. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group. Epilepsia. 1991;32(3):407-16.
17. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30(4):389-99.
18. O'Brien TJ, Cascino GD, So EL, Hanna DR. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51(4):1034-9.
19. O'Brien TJ, Meara FM, Matthews H, Vajda FJ. Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology. 2001;57(8):1508-10.
20. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia. 2001;42(9):1156-9.
21. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094-120.